Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001213900-25-096198
Filing Date
2025-10-03
Accepted
2025-10-03 17:28:47
Documents
19

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0260073-s3_oruka.htm S-3 355573
2 SALES AGREEMENT BETWEEN ORUKA THERAPEUTICS, INC. AND TD SECURITIES (USA) LLC, DA ea026007301ex1-2_oruka.htm EX-1.2 199650
3 OPINION OF DAVIS POLK & WARDWELL LLP RELATING TO THE BASE PROSPECTUS ea026007301ex5-1_oruka.htm EX-5.1 15692
4 OPINION OF DAVIS POLK & WARDWELL LLP RELATING TO THE SALES AGREEMENT PROSPECTUS ea026007301ex5-2_oruka.htm EX-5.2 8516
5 CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING ea026007301ex23-1_oruka.htm EX-23.1 1931
6 FILING FEE TABLE ea026007301ex-fee_oruka.htm   iXBRL EX-FILING FEES 37068
7 GRAPHIC image_001.jpg GRAPHIC 4517
8 GRAPHIC ex5-1_001.jpg GRAPHIC 3073
9 GRAPHIC ex5-2_001.jpg GRAPHIC 3073
  Complete submission text file 0001213900-25-096198.txt   778867

Data Files

Seq Description Document Type Size
21 EXTRACTED XBRL INSTANCE DOCUMENT ea026007301ex-fee_oruka_htm.xml XML 11157
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-290718 | Film No.: 251375076
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)